Simcha Therapeutics

  • About
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Investors
  • Science
    • Overview
    • Pipeline
    • Publications
  • Patients
  • Culture & Careers
  • Partnering
  • News
    • Press Releases
    • Media
  • Contact

Growing IL-18 field looks to enhance cell therapies via decoy evasion

Immunotherapies for Cancer and More: Aaron Ring on The Long Run

Enlisting Next-Generation Cytokine Immunotherapies in the Fight Against Cancer

ASH22 could be IL-18’s watershed moment

Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise

Engineering a better immunotherapy to outwit cancer — and launch a biotech

Simcha debuts with $25M to advance custom-built IL-18 for cancer

Simcha Therapeutics logo

© 2025 Simcha Therapeutics

SIMCHA, SIMCHA THERAPEUTICS, and the Simcha Therapeutics logo are registered trademarks of Simcha Therapeutics, Inc. Unauthorized use is prohibited.

Explore

  • About
  • Science
  • Patients
  • Culture & Careers
  • Partnering
  • News
  • Contact

Follow

Legal

  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Investors
  • Science
    • Overview
    • Pipeline
    • Publications
  • Patients
  • Culture & Careers
  • Partnering
  • News
    • Press Releases
    • Media
  • Contact